by nobilistx | Jun 22, 2020 | Uncategorized |
The National Institute on Drug Abuse (NIDA), one of the components of the National Institutes of Health (NIH), announced its 5th “$100,000 for Start a SUD Startup” Challenge. The Challenge goal is to support research ideas that would further an understanding of...
by nobilistx | May 2, 2020 | Uncategorized |
PORTLAND, Ore., May 2, 2020 – Nobilis Therapeutics announced today the issuance of a Notice of Allowance (European Patent Application No: 16815312.0) for a patent titled “Therapeutic immune modulation using noble gas compositions.” “We have uncovered substantial...
by nobilistx | Apr 10, 2020 | Uncategorized |
We are all consumed by the escalating COVID-19 pandemic that is likely to become much worse in the coming weeks. However, given the situation in China, it is likely that within several months the situation will stabilize and we will begin the recovery process. But as...
by nobilistx | Feb 28, 2020 | Uncategorized |
February 28, 2020. Portland, Oregon. Nobilis Therapeutics has announced that it has fully endorsed the grant application to conduct an Investigator-Initiated Clinical Trial of NBTX-001 in patients with Obsessive Compulsive Syndrome (OCD). The grant has been submitted...
by nobilistx | Jan 3, 2020 | Uncategorized |
Nobilis Therapeutics will participate in the 38th Annual J.P. MORGAN Healthcare Conference that will take place on January 13-16, 2020. If you are interested in scheduling a meeting with Company’s CEO, Dr. Vlad Bogin, please email us at [email protected] We...
